Table 1 Patients’ characteristics by study phase
Characteristic | Study phase | ||||
|---|---|---|---|---|---|
Control | Transition | Intervention | Total: | Â | |
n (%) | n (%) | n (%) | N (%) | p value^ | |
All patients: | 505 (100%) | 159 (100%) | 407 (100%) | 1071 (100%) | Â |
Age | |||||
 Median (years) | 65.0 | 65.0 | 65.0 | 65.0 |  |
 Quartiles (years) | 59–68 | 58–69 | 61–69 | 60–69 |  |
Age group | |||||
 40–59 | 128 (25%) | 43 (27%) | 81 (20%) | 252 (24%) | 0.145 |
 60–69 | 284 (56%) | 84 (53%) | 231 (57%) | 599 (56%) |  |
 70+ | 93 (18%) | 32 (20%) | 95 (23%) | 220 (21%) |  |
Extracapsular extension | |||||
 No | 96 (19%) | 27 (17%) | 69 (17%) | 192 (18%) | 0.511 |
 Yes | 406 (80%) | 131 (82%) | 338 (83%) | 875 (82%) |  |
 Unsure | 3 (1%) | 1 (1%) | 0 (0%) | 4 (0%) |  |
Positive surgical margin | |||||
 No | 229 (45%) | 69 (43%) | 198 (49%) | 496 (46%) | 0.087 |
 Yes | 276 (55%) | 89 (56%) | 204 (50%) | 569 (53%) |  |
 Unsure | 0 (0%) | 1 (1%) | 5 (1%) | 6 (1%) |  |
Seminal vesicle invasion | |||||
 No | 395 (78%) | 131 (82%) | 339 (83%) | 865 (81%) | 0.231 |
 Yes | 109 (22%) | 28 (18%) | 66 (16%) | 203 (19%) |  |
 Unsure | 1 (0%) | 0 (0%) | 2 (0%) | 3 (0%) |  |
Regional lymph node involvement | |||||
 No | 305 (60%) | 98 (62%) | 278 (68%) | 681 (64%) | 0.035 |
 Yes | 30 (6%) | 5 (3%) | 25 (6%) | 60 (6%) |  |
 Unsure | 170 (34%) | 56 (35%) | 104 (26%) | 330 (31%) |  |
Post-operative Gleason grade | |||||
 6–7 | 395 (78%) | 133 (84%) | 344 (85%) | 872 (81%) | 0.132 |
 8 | 30 (6%) | 3 (2%) | 18 (4%) | 51 (5%) |  |
 9–10 | 77 (15%) | 22 (14%) | 42 (10%) | 141 (13%) |  |
 Unsure | 3 (1%) | 1 (1%) | 3 (1%) | 7 (1%) |  |
Number of co-morbidities | |||||
 0 | 103 (20%) | 19 (12%) | 70 (17%) | 192 (18%) | 0.050 |
 1 | 72 (14%) | 19 (12%) | 45 (11%) | 136 (13%) |  |
 2 | 74 (15%) | 23 (14%) | 49 (12%) | 146 (14%) |  |
 3+ | 256 (51%) | 98 (62%) | 243 (60%) | 597 (56%) |  |
Maximum PSA level within 4Â months after RP (ng/ml) | |||||
  < 0.1 | 399 (79%) | 137 (86%) | 339 (83%) | 875 (82%) | 0.224 |
  ≥ 0.1 | 83 (16%) | 16 (10%) | 51 (13%) | 150 (14%) |  |
 No PSA test recorded | 23 (5%) | 6 (4%) | 17 (4%) | 46 (4%) |  |
Site | |||||
 Site 1 | 27 (5%) | 14 (9%) | 48 (12%) | 89 (8%) | < 0.001 |
 Site 2 | 11 (2%) | 2 (1%) | 12 (3%) | 25 (2%) |  |
 Site 3 | 68 (13%) | 39 (25%) | 120 (29%) | 227 (21%) |  |
 Site 4 | 51 (10%) | 12 (8%) | 54 (13%) | 117 (11%) |  |
 Site 5 | 23 (5%) | 3 (2%) | 19 (5%) | 45 (4%) |  |
 Site 6 | 77 (15%) | 21 (13%) | 36 (9%) | 134 (13%) |  |
 Site 7 | 81 (16%) | 26 (16%) | 34 (8%) | 141 (13%) |  |
 Site 8 | 120 (24%) | 26 (16%) | 52 (13%) | 198 (18%) |  |
 Site 9 | 47 (9%) | 16 (10%) | 32 (8%) | 95 (9%) |  |